Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block
Rattachement africain : us, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Buprenorphine is a μ-opioid receptor (MOR) partial agonist used to manage pain and addiction. QTC prolongation that crosses the 10 msec threshold of regulatory concern was observed at a supratherapeutic dose in two thorough QT studies for the transdermal buprenorphine product BUTRANS®. Because QTC prolongation can be associated with Torsades de Pointes (TdP), a rare but potentially fatal ventricular arrhythmia, these results have led to further investigation of the electrophysiological effects of buprenorphine. Drug-induced QTC prolongation and TdP are most commonly caused by acute inhibition of hERG current (IhERG) that contribute to the repolarizing phase of the ventricular action potentials (APs). Concomitant inhibition of inward late Na+ (INaL) and/or L-type Ca2+ (ICaL) current can offer some protection against proarrhythmia. Therefore, we characterized the effects of buprenorphine and its major metabolite norbuprenorphine on cardiac hERG, Ca2+, and Na+ ion channels, as well as cardiac APs. For comparison, methadone, a MOR agonist associated with QTC prolongation and high TdP risk, and naltrexone and naloxone, two opioid receptor antagonists, were also studied. Whole cell recordings were performed at 37°C on cells stably expressing hERG, CaV1.2, and NaV1.5 proteins. Microelectrode array (MEA) recordings were made on human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The results showed that buprenorphine, norbuprenorphine, naltrexone, and naloxone had no effect on IhERG, ICaL, INaL, and peak Na+ current (INaP) at clinically relevant concentrations. In contrast, methadone inhibited IhERG, ICaL, and INaL. Experiments on iPSC-CMs showed a lack of effect for buprenorphine, norbuprenorphine, naltrexone, and naloxone, and delayed repolarization for methadone at clinically relevant concentrations. The mechanism of QTC prolongation is opioid moiety-specific. This remains undefined for buprenorphine, while for methadone it involves direct hERG channel block. There is no evidence that buprenorphine use is associated with TdP. Whether this lack of TdP risk can be generalized to other drugs with QTC prolongation not mediated by acute hERG channel block warrants further study.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block
- Date Crossref
- 06/11/2020
- Éditeur
- Public Library of Science (PLoS)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
United States Food and Drug Administration pays non établi dans la noticeOrganisme public
-
Center for Drug Evaluation and Research pays non établi dans la noticeStructure de recherche
-
Center for Devices and Radiological Health pays non établi dans la noticeÉtablissement de santé
-
Vertex Pharmaceuticals (United Kingdom) pays non établi dans la noticeEntreprise
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Office of Science pays non établi dans la noticeOrganisme public
-
Massachusetts General Hospital pays non établi dans la noticeÉtablissement de santé
-
Office of Clinical Pharmacology Division of Applied Regulatory Science pays non établi dans la noticeÉtablissement de santé
-
Division of Immunology and Hematology Devices pays non établi dans la noticeInstitution
-
CiPALab pays non établi dans la noticeStructure de recherche
-
Vertex Pharmaceuticals (Europe) Ltd pays non établi dans la noticeEntreprise
-
Division of Cardiology and Nephrology pays non établi dans la noticeInstitution
United States Food and Drug Administration, Center for Drug Evaluation and Research et Center for Devices and Radiological Health, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.